Sonrotoclax Plus Zanubrutinib for CLL: Recruiting Clinical Trial

The treatment landscape for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has changed dramatically in the past decade. New targeted therapies have revolutionized CLL / SLL treatment and significantly improved patient outcomes. In this interview, Dr. Brian Koffman spoke with Dr. Lori Leslie, a lymphoma and CLL specialist at the John Theurer Cancer Center in Hackensack, New Jersey. They discussed a new phase 3 clinical trial that tests sonrotoclax (BGB-3111), a new BCL2 inhibitor, combined with zanubrutinib for CLL. This clinical trial of sonrotoclax is currently recruiting patients. Learn more on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT0... Read the full article on CLL Society's website at: https://cllsociety.org/2024/03/recrui... __________________________________________________________________________________________ CLL Society Website: https://cllsociety.org/ Facebook:   / cllsociety   Twitter:   / cllsociety   LinkedIn:   / cll-society